Human Genome Sciences — Corporate Update (September 2010)
30 slides from Human Genome Sciences's corporate update, Sep 13, 2010
Slide 1: Poised for the Market: Preparing for Launch and Future Growth
com com POISED for the MARKET: PREPARING FOR LAUNCH AND FUTURE GROWTH Company Update September, 2010
Slide 2: Note Regarding Forward-Looking Statements
Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward- looking statements are based on Human Genome S
Slide 3: A Formula for Sustained Growth
A Formula for Sustained Growth BENLYSTA: potential blockbuster First Phase 3 trials in lupus to achieve primary endpoint PDUFA target Dec. 9, 2010 Primary U.S. market-200,000 patients with moderate-severe systemic lupus Broad global partnership with GSK Mean analyst estimate for peak BENLYSTA sales:
Slide 4: A Formula for Growth: Near Term 2010-2014
A Formula for Growth: Near Term 2010-2014 Potential blockbuster product: BENLYSTA First Phase 3 trials in lupus to achieve primary endpoint BLA submitted, PDUFA target December 9th Primary market: 200,000 patients in U.S. with moderate-severe systemic lupus 1.5 million patients* in U.S. have lupus a
Slide 5: A Formula for Growth: Long Term 2014 and Beyond
A Formula for Growth Long Term: 2014 and Beyond BENLYSTA studies planned/underway for new indications and dosage form Sub Q formulation potentially increases dosing convenience for patients New studies planned in related B-cell diseases: Vasculitis, post-renal transplant, Sjogren's, Waldenstrom's, p
Slide 6: Emerging Mid-Stage HGS Pipeline, Late-Stage GSK Products Promise Future Growth
EMERGING Mid-Stage HGS Pipeline, Late-Stage GSK Products Promise Future Growth BENLYSTA(r) Anti-CCR5 mAb HGS-1029 BENLYSTA BENLYSTA BENLYSTA Raxibacumab Mapatumumab LEAD GSK SYNCRIA(r) Darapladib Systemic Lupus1 Ulcerative Colitis4 Cancer Additional Autoimmune Vasculitis2 Kidney Transplant3 Inhalati
Slide 7: What is Systemic Lupus Erythematosus (SLE)?
SLE is a chronic, life-threatening autoimmune disease that can damage any part of the body, including skin, joints and major organ systems. Lupus can occur at any age, but appears mostly in young women ages 15 to 45. Symptoms may include extreme fatigue, debilitating pain, swollen joints, unexplaine
Slide 8: Unmet Need Remains with Current Therapies
Unmet Need Remains with Current Therapies Class Medication Toxicities to Monitor Corticosteroids Prednisone Hypertension, hyperglycemia, hyperlipidemia, hypokalemia, osteoporosis, osteonecrosis, cataracts, weight gain, infections, fluid retention Antimalarials Hydroxychloroquine CNS effects, rashes,
Slide 9: Blockbuster Potential with Significant U.S. Patient Population
Blockbuster Potential with Significant U.S. Patient Population 1,500,000 Patients Lupus and Related Conditions* Mild 33% Severe 22% 325,000 SLE Patients Treated by Rheumatologists** Moderate 45% Other forms of lupus Undiagnosed Primary care treated Primary Target 200,000 ** Per primary market resear
Slide 10: BENLYSTA Targets SLE Patients with Significant Unmet Medical Need
BENLYSTA Targets SLE Patients with Significant Unmet Medical Need High dose steroids / immunosuppressants with or without disease activity Uncontrolled on first-line treatment Well controlled on first-line treatment BENLYSTA Primary Target: 200,000 Patients (U.S.) First Line: Low dose steroid / hydr
Slide 11: BENLYSTA (Belimumab): First Drug From Our Genomic Efforts
BENLYSTA (Belimumab) First Drug From Our Genomic Efforts Addressing an Important Unmet Medical Need in SLE BLyS and B cells are major factors in the pathogenesis of SLE Activity of BENLYSTA through the inhibition of BLyS increases the potential for autoreactive B cells to undergo the normal process
Slide 12: First Two Positive Phase 3 Trials in Lupus
First Two Positive Phase 3 Trials in Lupus Patient Response at Week 52 % Subjects Generally well tolerated with rates of overall adverse events, serious and/or severe adverse events, all infections, and serious and/or severe infections comparable between BENLYSTA and placebo p=0.0006 p=0.021 BLISS-5
Slide 13: BENLYSTA Met Primary Endpoint in BLISS-52
BENLYSTA Met Primary Endpoint in BLISS-52* Summary** Reduced SLE disease activity Improved response rates with even greater differentiation from placebo using higher thresholds for improvement Reduced overall and severe SLE flare rates Delayed time-to-first SLE flare Demonstrated steroid-sparing eff
Slide 14: BLISS-52: SRI Response Rates
BLISS-52: SRI Response Rates BLISS-52 SOC Plus BLISS-52 SOC Plus BLISS-52 SOC Plus Placebo n=287 (%) 1 mg/kg n=288 (%) 10 mg/kg n=290 (%) SRI 4a 43.6 51.4 57.6 p value 0.013 0.0006 SRI 5b 29.3 37.5 44.8 p value 0.0027 <0.0001 SRI 6b 28.2 36.8 43.8 p value 0.002 <0.0001 SRI 7b,c 17.1 22.2 26.6 p valu
Slide 15: BENLYSTA Met Primary Endpoint in BLISS-76
BENLYSTA Met Primary Endpoint in BLISS-76* Summary** At Week 76, Benlysta plus SOC showed higher response rates compared with placebo plus SOC measured by SRI Improved response rates using higher thresholds for SELENA SLEDAI improvement (SRI 5-7) at Weeks 52 and 76, with even greater differentiation
Slide 16: BLISS-76: SRI Response Rates
BLISS-76 Week 52 SOC Plus BLISS-76 Week 52 SOC Plus BLISS-76 Week 52 SOC Plus BLISS-76 Week 76 SOC Plus BLISS-76 Week 76 SOC Plus BLISS-76 Week 76 SOC Plus Placebo n=275 (%) 1 mg/kg n=271 (%) 10 mg/kg n=273 (%) Placebo n=275 (%) 1 mg/kg n=271 (%) 10 mg/kg n=273 (%) SRIa 33.5 40.6 43.2 32.4 39.1 38.5
Slide 17: Pricing BENLYSTA Right for the Market
Pricing BENLYSTA Right for the Market Pricing in comparable categories Quantitative price sensitivity research Economic burden of disease analysis Pharmacoeconomic modeling HGS and GSK to make pricing decision close to launch * Estimated Wholesale Acquisition Price per HGS Management ** Includes pri
Slide 18: Experienced Sales Organization
Experienced Sales Organization Sales management team of 13 onboard 3 Area Managers and 10 District Managers Formerly with Abbott, Amgen, Biogen, BMS, Centocor, Genentech, Eisai Significant experience with rheumatology biologics, including Remicade(r), Rituxan(r), Orencia(r), Enbrel(r), Actemra(r) Fu
Slide 19: Manufacturing Supply Meets Demand
Manufacturing Supply Meets Demand Lonza to Triple Capacity HGS responsible for worldwide supply State-of-the-art process development and manufacturing capability 2 x 20K liters in-house manufacturing capacity for BENLYSTA Sufficient to produce worldwide supply for first 2-3 years of launch Full rang
Slide 20: BENLYSTA Discovered by HGS, Developed by HGS/GSK
BENLYSTA Discovered by HGS, Developed by HGS/GSK 1996: BLyS discovered 1999: BLyS discovery published in Science 2001: Phase 1 trial for BENLYSTA initiated 2003: Phase 1 trial results found BENLYSTA well- tolerated and biologically active in SLE patients 2003: Phase 2 SLE trial initiated 2004: Phase
Slide 21: Broad Potential Beyond Initial Market Entry in SLE
Subcutaneous Formulation Improves convenience for some patients Multi-Center Phase 2 Trials Additional Indications under consideration include: Vasculitis Post-renal transplant Proof-of-Concept Studies Ongoing or imminent studies in certain new indications, including: Sjogren's Syndrome Waldenstrom'
Slide 22: BENLYSTA Potentially Addresses Large, Underserved Markets
BENLYSTA Potentially Addresses Large, Underserved Markets Patients SLE1 Vasculitis2 Post-Renal Transplant2 Sjogren's3/Waldenstrom's4 Pre-Transplant2 ITP1 1U.S. and top 5 largest European markets. 2U.S. only. 3Severe, diagnosed U.S. patients only. 4Worldwide. Source: HGS/GSK estimates. The population
Slide 23: Mean Analyst Estimate of Peak BENLYSTA Sales: $4.1 Billion
$4.1B Billions Bernstein BofA JPMorgan Piper RBC ThinkEquity Collins Mean ISI JMP Leerink MCH Citi Stifel Barclays Lazard Mean Analyst Estimate of Peak BENLYSTA Sales: $4.1 Billion Estimates as of September 8, 2010. Please note that neither HGS nor GSK endorses or adopts these estimates as its own.
Slide 24: Raxibacumab: First Product Sales and Second Order Achieved
Raxibacumab: First Product Sales and Second Order Achieved First 20,000 doses delivered H1 2009 to the U.S. Strategic National Stockpile; $163 million in revenue recognized through Q2 2009 45,000 more doses to be delivered over a three-year period; $142 million award ~14,000 doses delivered and $44
Slide 25: GSK Products Offer Significant Therapeutic and Commercial Potential: Darapladib
GSK Products Offer Significant Therapeutic and Commercial Potential Darapladib
Slide 26: GSK Products: SYNCRIA
Eight Phase 3 studies ongoing to demonstrate durable efficacy and safety as mono- and add-on therapy in patients with type 2 diabetes Primary endpoint for all eight studies: change from baseline in HbA1c compared with placebo and/or active comparators Expected study duration of up to 3 years GSK Pro
Slide 27: TRAIL Pathway Offers Therapeutic Opportunities Across a Broad Range of Cancers
TRAIL Pathway Offers Therapeutic Opportunities Across a Broad Range of Cancers Mapatumumab (HGS-ETR1) Targets TRAIL apoptosis pathway Proof-of-concept phase under way Phase 2 randomized chemotherapy combo trials-randomization stage of hepatocellular trial expected to begin year-end 2010 HGS1029 (IAP
Slide 28: Strong Financial Position to Fuel Product Launches, Pipeline Advancement
Strong Financial Position to Fuel Product Launches, Pipeline Advancement Cash and investments at June 30, 2010: ~ $1.1 billion Expected net cash burn 2010: $300-$350 million Expected cash and investments at year-end 2010: $840-890 million Products Nearing Commercialization Strong Cash Position High-
Slide 29: Preparing for Launch, Future Growth
Preparing for Launch, Future Growth World-Class Partner Commercial Readiness Manufacturing Excellence Potential Blockbuster Product Seasoned Leadership Pipeline to Fuel Future Growth A Robust Formula for Commercial Success
Slide 30: The End
com com THE END Company Update September, 2010
Human Genome Sciences — Corporate Update (September 2010) on 6ix